StockData

Spero Therapeutics vs Tango Therapeutics

SPRO and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SPRO and TNGX compare

Tango Therapeutics is the larger company, worth 71 times as much as Spero Therapeutics ($3.7B against $52.5M).

Tango Therapeutics grew revenue faster over the last twelve months (121% versus −3.3% for Spero Therapeutics).

Spero Therapeutics keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −230% at Tango Therapeutics.

Spero Therapeutics scores higher on the StockData Score (11 against 10 for Tango Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSPROTNGX
Size and price
Market cap$52.5M$3.7B
Share price$0.901$22.11
Change, 1 year−62.6%171%
Change, 5 years−94.0%114%
Beta (5Y)1.341.67
Employees25137
StockData Score
Total score11 (better)10
Valuation score3 (better)0
Growth score02 (better)
Performance score3 (better)2
Health score56 (better)
Dividend score00
Valuation
P/E22.5×–
P/S1.1× (better)69.3×
P/B1.2× (better)3.6×
EV/EBITDA0.3×–
FCF yield–−3.9%
Fair value$1.64$9.71
Margin of safety44.9% (better)−128%
Growth
Revenue growth (TTM)−3.3%121% (better)
Revenue growth, 5Y average48.2%52.1% (better)
Profitability
Operating margin12.8% (better)−253%
Net margin15.7% (better)−230%
FCF margin–−268%
Return on equity19.2% (better)−21.3%
Financial health
Debt / equity0.000.00
Current ratio6.1250.82 (better)
Altman Z-score−6.4945.17 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions36.9%127%
Held by insiders24.6%11.7%
Insider net buying, 12 months−$499K (better)−$8.1M
Short interest, % of float1.8%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.